Outcomes of daratumumab, pomalidomide, and dexamethasone (DPd) followed by high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) in patients with relapsed/refractory multiple myeloma RRMM

Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Al-Ola Abdallah, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, Shebli Atrash, Hameem Kawsar, Monia Sigle, Leyla Shune, Joseph McGuirk, Siddhartha Ganguly
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research